RGL-270
/ Shanghai Regenelead Therapies
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 06, 2025
An open, multi-center phase I clinical study to evaluate the safety, tolerance, pharmacokinetics and immunogenicity of personalized new antigen RGL-270 single drug and combined with adebelimab in patients at high risk of recurrence after radical treatment of malignant solid tumors
(ChiCTR)
- P1 | N=198 | Not yet recruiting | Sponsor: Fudan University Shanghai Cancer Center; Shanghai Regenelead Theraples,Co,Ltd.
New P1 trial • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Mucosal Melanoma • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • ALK • BRAF • EGFR
1 to 1
Of
1
Go to page
1